J Res Notes | Volume 1, Issue 1 | Research Article | Open Access
Kemale Gencali1, Itir Şirinoğlu Demiriz2*, Yildiz Okuturlar3 and Ümit Barbaros Üre4
1Department of Internal Medicine, Bakırköy Dr. Sadi Konuk Research and Training Hospital, Turkey
2Department of Hematology, Bakırköy Dr. Sadi Konuk Research and Training Hospital, Turkey
3Department of Internal Medicine, Acibadem University Hospital Atakent, Turkey
4Department of Hematology, Koc University, Turkey
*Correspondance to: Itır Şirinoğlu Demiriz
Fulltext PDFObjective: Chronic Myeloproliferative Neoplasia (CMPN) are a group of diseases characterized by uncontrolled proliferation of one or more lines of myeloerythroid cells in bone marrow and increased number of mature or immature cells in the peripheral blood and are associated with hemostasis and thrombosis anomalies as well as progression to acute leukemia. Presence of JAK2 V617F mutation has been included in the revised WHO criteria for the diagnosis of PV, ET and PMF.
Materials and Methods: This study is focused on clinical and prognostic factors such as age, thrombosis, leukocytosis, platelet count, previous history of thrombotic or hemorrhagic events, disease duration, hepatomegaly, splenomegaly and their relations with this mutation and cardiovascular risk factors in 120 patients with CMPN. The considered cardiovascular risk factors were arterial hypertension, diabetes, smoking, hypercholesterolemia, and a first degree relative with a history of thrombosis.
Results: The study included 120 patients with CMPN who were evaluated in hematology clinic. Study groups were consisted of 51 patients with PV, 44 patients with ET, 22 patients with unclassified CMPN, and 3 patients with PMF. The study population was consisted of 61 males (50, 3%) and 59 females (49, 17%). Patients’ mean age at the time of diagnosis was 54 years (range 19 to 84); 65% of the patients (n=78) were under 60-year-old, and 35% of the patients (n=42) were under 60-year-old or older. JAK 2 V617F mutation was positive in 44 (46.8%) patients; JAK 2 mutation was negative in 50 (53.19%) patients. JAK2 V617F positivity rate was 38.6% in PV, 43.1% in ET and 4.55% in PMF, and 13.6% in unclassified CMPN. In our study the incidence of JAK 2 mutation were significantly lower in patients diagnosed with of PV. The incidence of the JAK2 mutation was significantly lower in patients with a diagnosis of PV. Prevalence of this mutation in ET group was correlated with literature, but prevalence of JAK2 mutation in PV and in PMF was not correlated with the literature. No statistically difference was observed in regard to distributions of JAK 2 (-) and JAK 2 (+) among disease groups.
Conclusion: We did not find any statistical difference among the groups in regard to thrombosis. CVD, JAK 2 mutation, HT was not associated with risk of thrombosis. There were no statistical differences in presence of diabetes and dyslipidemia between thrombosis (-) and thrombosis (+) groups, but the presence of smoking in thrombosis (+) group were significantly higher than thrombosis (-) group. More studies are needed in regard to define the relationship between JAK2 V617F mutation and clinical and laboratory findings of patients with CMPN.
Chronic myeloproliferative neoplasia; JAK2 V617F mutation; Thrombosis; Cardiovascular risk factors
Gencali K, Demiriz IŞ, Okuturlar Y, Üre ÜB. The Analysis of the Correlation between Chronic Myeloproliferative Neoplasms and Cardiovasculary Risk Factors. J Res Notes. 2018;1(1):1003.